Schedule 13G ownership disclosure

X4 Pharmaceuticals Inc

Common Stock, par value $0.001 per share · CUSIP: 98420X202

Event date: 2025-09-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Bain Capital Life Sciences Fund, L.P.

    Shares: 2,436,588 · Class: 9.99%

  • Bain Capital Life Sciences Fund II, L.P.

    Shares: 2,436,588 · Class: 9.99%

  • BCIP Life Sciences Associates, LP

    Shares: 2,436,588 · Class: 9.99%

  • BCLS II Investco, LP

    Shares: 2,436,588 · Class: 9.99%

  • BCLS I Investco, LP

    Shares: 2,436,588 · Class: 9.99%

  • BCLS II Equity Opportunities, LP

    Shares: 2,436,588 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-25-203640
Form type
SCHEDULE 13G
Filer
Bain Capital Life Sciences Fund, L.P.
CIK
CIK 1687968
Filed
Sep 15, 2025
Reporting period
Sep 09, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub